Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 43Thromboembolism 1Prostate Adenocarcinoma 1Neoplasm Metastasis 1Kidney Neoplasms 1Carcinoma, Renal Cell 1

Interventions

Magnetic Resonance Spectroscopy 5Radiosurgery 4luprolide acetate gel depot 3enzalutamide 3Radiotherapy 3Radiation 3Leuprolide 3Goserelin 3relugolix 2gallium 68 PSMA-11 2bicalutamide 2acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 2Triptorelin Pamoate 2Specimen Handling 2Proton Therapy 2Biopsy 2radium Ra 223 dichloride 1niraparib 1histrelin 1fluciclovine F-18 1flibanserin 1entinostat 1darolutamide 1atezolizumab 1apalutamide 1abiraterone 1X-Rays 1Watchful Waiting 1Surveys and Questionnaires 1Surgical Procedures, Operative 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Prostate Adenocarcinoma × Estramustine × Genitourinary × Clear all
NCT00183924 2014-05-22

Estramustine, Docetaxel, and Carboplatin for Patients With Hormone Refractory Prostate Cancer Progressing After Mitoxantrone-Based Chemotherapy.

University of Southern California

Phase 2 Completed
20 enrolled
Genitourinary

Prostate Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡